Search research articles
Contact Us
Filters
Showing results (1-10 of 46) with videos related to
Page
of 5
Sort By:
Therapie
|
April 27, 1999
Comparing therapeutic benefit and risk
R H Meyboom, A C Egberts
Drug Safety
|
July 6, 2000
An ABC of drug-related problems
R H Meyboom, M Lindquist, A C Egberts
Journal of Analytical Toxicology
|
March 10, 1998
Performance of Abusign drugs-of-abuse slide tests with particluar emphasis on concentrations near the cutoff: comparison with FPIA-ADx and confirmation of results with GC-MS
J J Ros, M G Pelders, A C Egberts
Nederlands Tijdschrift Voor Geneeskunde
|
February 8, 1992
[Physician and pharmaceutical industry. II. Postmarketing surveillance]
A C Egberts, A W Lenderink, H ter Steege
Nederlands Tijdschrift Voor Geneeskunde
|
September 24, 1999
[Clinical researchers and pharmaceutical industry. The examples of troglitazone and mibefradil]
M L Bouvy, A C Egberts, H G Leufkens
The New Zealand Medical Journal
|
April 21, 1999
Mirtazapine and the granulocytes--so far so good
R H Meyboom, I R Edwards, A C Egberts
Journal of Pharmaceutical and Biomedical Analysis
|
March 4, 2000
Analysis of low concentration sufentanil citrate/bupivacaine hydrochloride admixtures, using solid phase extraction followed by high-performance liquid chromatography
K L Movig, M C Langen, A C Egberts
International Clinical Psychopharmacology
|
May 1, 1997
Serotonin syndrome attributed to tramadol addition to paroxetine therapy
A C Egberts, J ter Borgh, C C Brodie-Meijer
Journal of Analytical Toxicology
|
September 22, 2000
Automated extraction of 11-nor-delta9-tetrahydrocannabinol carboxylic acid from urine samples using the ASPEC XL solid-phase extraction system
M C Langen, G A de Bijl, A C Egberts
European Journal of Pediatrics
|
December 11, 1999
Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis
R A de Moor, A C Egberts, C H Schröder
Page
of 5
Search research articles
Search
Showing results (1-10 of 46) with videos related to
Sort By:
Page
of 5
Therapie
|
April 27, 1999
Comparing therapeutic benefit and risk
R H Meyboom, A C Egberts
Drug Safety
|
July 6, 2000
An ABC of drug-related problems
R H Meyboom, M Lindquist, A C Egberts
Journal of Analytical Toxicology
|
March 10, 1998
Performance of Abusign drugs-of-abuse slide tests with particluar emphasis on concentrations near the cutoff: comparison with FPIA-ADx and confirmation of results with GC-MS
J J Ros, M G Pelders, A C Egberts
Nederlands Tijdschrift Voor Geneeskunde
|
February 8, 1992
[Physician and pharmaceutical industry. II. Postmarketing surveillance]
A C Egberts, A W Lenderink, H ter Steege
Nederlands Tijdschrift Voor Geneeskunde
|
September 24, 1999
[Clinical researchers and pharmaceutical industry. The examples of troglitazone and mibefradil]
M L Bouvy, A C Egberts, H G Leufkens
The New Zealand Medical Journal
|
April 21, 1999
Mirtazapine and the granulocytes--so far so good
R H Meyboom, I R Edwards, A C Egberts
Journal of Pharmaceutical and Biomedical Analysis
|
March 4, 2000
Analysis of low concentration sufentanil citrate/bupivacaine hydrochloride admixtures, using solid phase extraction followed by high-performance liquid chromatography
K L Movig, M C Langen, A C Egberts
International Clinical Psychopharmacology
|
May 1, 1997
Serotonin syndrome attributed to tramadol addition to paroxetine therapy
A C Egberts, J ter Borgh, C C Brodie-Meijer
Journal of Analytical Toxicology
|
September 22, 2000
Automated extraction of 11-nor-delta9-tetrahydrocannabinol carboxylic acid from urine samples using the ASPEC XL solid-phase extraction system
M C Langen, G A de Bijl, A C Egberts
European Journal of Pediatrics
|
December 11, 1999
Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis
R A de Moor, A C Egberts, C H Schröder
Page
of 5